Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· April 11, 2026

Is It Too Late To Consider AstraZeneca (LSE:AZN) After Its 54.8% One-Year Surge?

View original at finance.yahoo.com

Is It Too Late To Consider AstraZeneca (LSE:AZN) After Its 54.8% One-Year Surge? Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide…

Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

The DCF model arrives at an estimated intrinsic value of US$238.68 per share for AstraZeneca
60% confidence
AstraZeneca's DCF analysis suggests the stock is undervalued by 36.2%
60% confidence
AstraZeneca has a valuation score of 3 out of 6
60% confidence

Data points we hold from this source

AstraZeneca AB · stock return 30day	5.2 percent
AstraZeneca AB · stock return 1year	54.8 percent
AstraZeneca AB · free cash flow	9.49 USD
AstraZeneca AB · stock return ytd	12.1 percent
AstraZeneca AB · projected free cash flow	20.16 USD
AstraZeneca AB · valuation score	3 out_of_6
AstraZeneca AB · intrinsic value dcf	238.68 USD
AstraZeneca AB · stock return 7day	-0.6 percent